De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Beximco Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	15.4yrs
Gemiddelde ambtstermijn bestuur	4.1yrs

Recente managementupdates

Recent updates

CEO

Beximco Pharmaceuticals heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mohammad Nawaz	Chief Financial Officer	15.8yrs	geen gegevens	geen gegevens
S. M. Reza	Chief Operating Officer	15.4yrs	geen gegevens	geen gegevens
Jamal Choudhury	Director of Accounts & Finance	no data	geen gegevens	geen gegevens
Rizvi Kabir	Director of Marketing	no data	geen gegevens	geen gegevens
M. A. Bhuiyan	General Manager of Human Resources	no data	geen gegevens	geen gegevens
Zakaria Chowdhury	Head of Distribution Services & Director of International Marketing	14.8yrs	geen gegevens	geen gegevens
Mohammad Ullah	Company Secretary & Executive Director	no data	geen gegevens	geen gegevens

15.4yrs

Gemiddelde duur

Ervaren management: Het managementteam van BXPHARMA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 15.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mohammad Ullah	Company Secretary & Executive Director	no data	geen gegevens	geen gegevens
Salman Rahman	Vice Chairman	no data	geen gegevens	2.04% BDT 592.9m
Abu Bakar Rahman	Director	31.8yrs	geen gegevens	geen gegevens
Osman Chowdhury	Director	no data	geen gegevens	geen gegevens
Iqbal Ahmed	Director	39.8yrs	geen gegevens	geen gegevens
Ahmed Sohail Rahman	Chairman	no data	geen gegevens	2.03% BDT 591.5m
Quamrun Ahmed	Non-Executive Director	3.9yrs	geen gegevens	geen gegevens
Mamtaz Ahmed	Independent Non-Executive Director	4.3yrs	geen gegevens	geen gegevens
Reem Shamsuddoha	Non-Executive Director	3.9yrs	geen gegevens	geen gegevens
Md. Hosein Khan	Independent Director	3.8yrs	geen gegevens	geen gegevens

4.1yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BXPHARMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

Beximco Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023

Less than half of directors are independent

Less than half of directors are independent

Beximco Pharmaceuticals Limited Announces Board Changes

Recent updates

Price target increased by 9.3% to ৳168

Third quarter 2024 earnings released: EPS: ৳3.06 (vs ৳2.13 in 3Q 2023)

Beximco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024

Second quarter 2024 earnings released: EPS: ৳3.21 (vs ৳2.77 in 2Q 2023)

Beximco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board

Upcoming dividend of ৳3.50 per share at 2.4% yield

Full year 2023 earnings released: EPS: ৳10.34 (vs ৳11.48 in FY 2022)

Beximco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 05, 2023

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023

Beximco Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 19, 2023

Third quarter 2023 earnings released: EPS: ৳2.13 (vs ৳2.47 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ৳2.77 (vs ৳3.84 in 2Q 2022)

Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022

Less than half of directors are independent

Full year 2022 earnings: EPS misses analyst expectations

Beximco Pharmaceuticals Limited Proposes Dividend for the Year Ended 30 June 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to ৳182

Less than half of directors are independent

Now 20% undervalued after recent price drop

Consensus EPS estimates increase by 18%

Second quarter 2022 earnings: EPS exceeds analyst expectations

Beximco Pharmaceuticals Limited Launches First Generic Version of Pfizer's COVID-19 Treatment Paxlovid

Upcoming dividend of ৳3.50 per share

Full year 2021 earnings released: EPS ৳11.49 (vs ৳7.88 in FY 2020)

Third quarter 2021 earnings released: EPS ৳3.28 (vs ৳2.02 in 3Q 2020)

Investor sentiment improved over the past week

Beximco Pharmaceuticals Limited Updates on the Supply of Covid-19 Vaccine

Second quarter 2021 earnings released: EPS ৳2.54 (vs ৳1.93 in 2Q 2020)

Analysts increase EPS estimates to ৳10.32

Price target raised to ৳114

Beximco Pharmaceuticals Limited Announces Board Changes

Beximco Pharmaceuticals Limited Provides Update on the Supply of COVID-19 Vaccine

Beximco Pharmaceuticals Limited Confirms Quamrun Naher Ahmed and Reem H. Shamsuddoha as Non-Executive Directors

Investor sentiment improved over the past week

New 90-day high: ৳170

New 90-day high: ৳159

Beximco Pharmaceuticals Limited Announces Directors Appointments

New 90-day high: ৳148

Price target raised to ৳113

New 90-day high: ৳148

Price target raised to ৳116

New 90-day high: ৳145

First quarter 2021 earnings released: EPS ৳2.65

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ৳8.67

Beximco Pharmaceuticals Limited Enters into A Memorandum of Understanding for the Supply and Distribution of 30 Million Doses of the Oxford University/AstraZeneca SARS-CoV-2 Vaccine, AZD1222, in Bangladesh

New 90-day high: ৳127

Beximco Pharmaceuticals Limited Receives US Food and Drug Administration (Fda) Approval for Antiarryhtmic Drug Flecainide

Price target raised to ৳105

New 90-day high - ৳116

CEO

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd